Adeza Biomedical Establishing Direct Sales Force For TLi Rapid fFN Assay
This article was originally published in The Gray Sheet
Executive Summary
Adeza Biomedical's TLi System rapid fetal fibronectin assay shaves roughly three hours of turnaround time off the firm's first-generation fFN test for assessing the risk of preterm labor.
You may also be interested in...
Adeza Likely To Use IPO Proceeds To Enlarge Preterm Birth Test Indication
Adeza Biomedical may use a portion of the $69 mil. it expects to generate from an initial public offering to expand the U.S. indication for its Fetal Fibronectin Test to women at "low-risk" of giving birth preterm
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”